Summit Therapeutics’ troubled C. difficile medicine may have a path forward after the FDA cleared a section of trail—however, it’s going to be a steep climb.
The California biotech met with the agency last week to discuss lead asset ridinilazole, which failed to outperform the common antibiotic vancomycin in a phase 3 clinical trial at the end of 2021. Summit has been looking for a way to advance the asset anyway, pitching potential partnerships or an acquisition as a way forward in March.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,